Equity

9 Months Ended

Sep. 30, 2012

Stockholders' Equity Note [Abstract]

Equity

Equity

Changes in equity for the nine months endedSeptember 30, 2012 and 2011 were as follows (in thousands, except share amounts):

	Gentiva Shareholders
	Common Stock			Additional Paid-in			Retained Earnings Accumulated			Accumulated Other Comprehensive			Treasury			Noncontrolling
	Shares	Amount		Capital			(Deficit)			Income (Loss)			Stock			Interests			Total
Balance at December 31, 2010	30,799,091	$	3,080	$	372,106		$	272,394		$	478		$	(12,484	)	$	2,658		$	638,232
Comprehensive (loss) income:
Net (loss) income	—	—		—			(455,110		)	—			—			452			(454,658		)
Changes in fair value of interest rate swaps	—	—		—			—			(768		)	—			—			(768		)
Realized loss on interest rate swaps	—	—		—			—			290			—			—			290
Total comprehensive (loss) income	—	—		—			(455,110		)	(478		)	—			452			(455,136		)
Income tax benefits associated with the exercise of non-qualified stock options	—	—		259			—			—			—			—			259
Equity-based compensation expense	—	—		6,259			—			—			—			—			6,259
Net issuance of stock upon exercise of stock options and under stock plans for employees and directors	464,680	47		6,969			—			—			—			—			7,016
Purchase of non-controlling interest	—	—		(352		)	—			—			—			32			(320		)
Distribution to partnership interests	—	—		—			—			—			—			(608		)	(608		)
Treasury shares:
Common stock received from Healthfield escrow (14,334 shares)	—	—		—			—			—			(394		)	—			(394		)
Balance at September 30, 2011	31,263,771	$	3,127	$	385,241		$	(182,716	)	$	—		$	(12,878	)	$	2,534		$	195,308
Balance at December 31, 2011	31,435,264	$	3,144	$	387,803		$	(178,131	)	$	—		$	(12,878	)	$	2,593		$	202,531
Comprehensive income:
Net income	—	—		—			18,226			—			—			624			18,850
Total comprehensive income	—	—		—			18,226			—			—			624			18,850
Equity-based compensation expense	—	—		5,722			—			—			—			—			5,722
Net issuance of stock upon exercise of stock options and under stock plans for employees and directors	391,177	39		2,381			—			—			—			—			2,420
Purchase of non-controlling interest	—	—		—			—			—			—			(1,113		)	(1,113		)
Distribution to partnership interests	—	—		—			—			—			—			(685		)	(685		)
Treasury shares:
Stock repurchase (605,077 shares)	—	—		—			—			—			(4,974		)	—			(4,974		)
Balance at September 30, 2012	31,826,441	$	3,183	$	395,906		$	(159,905	)	$	—		$	(17,852	)	$	1,419		$	222,751

Comprehensive loss amounted to $0.4 million and comprehensive income amounted to $18.9 million for the third quarter and first nine months of 2012, respectively, as compared to comprehensive losses of $473.6 million and $455.1 million for the third quarter and first nine months of 2011, respectively. The amounts reflected in accumulated other comprehensive income (loss) for the nine months endedSeptember 30, 2011 are reflected net of tax of approximately $0.4 million.

On April 14, 2005, the Company announced that its Board of Directors had authorized the repurchase of up to 1,500,000 shares of the Company’s outstanding common stock (the “2005 Repurchase Program”). In addition, on March 13, 2012, the Company announced that its Board of Directors had authorized the repurchase of up to $5,000,000 of shares of the Company’s outstanding common stock (the “2012 Repurchase Program”). During the nine months endedSeptember 30, 2012, the Company repurchased 605,077 shares of its common stock at an average cost of $8.22 per share and a total cost of approximately $5.0 million. Due to these repurchases, as of September 30, 2012, the Company had no remaining shares authorized under the 2005 Repurchase Program and had remaining authorization under the 2012 Repurchase Program to repurchase common stock with an aggregate purchase price of up to $1.5 million, subject to the additional limitations set forth below.

The Company’s Credit Agreement provides for repurchases of the Company’s common stock not to exceed $5.0 million per year, and not to exceed $20.0 million per year if the consolidated leverage ratio is less than or equal to 3.5:1 immediately after giving effect on a pro forma basis to the repurchase. The indenture governing the Company’s Senior Notes also contains limitations on the Company’s repurchases of its common stock.